Goto Yasunobu, Yamagata Sen
Department of Neurosurgery, Kurashiki Central Hospital, Japan.
No Shinkei Geka. 2004 Jun;32(6):579-84.
Cerebral vasospasm remains a leading cause of morbidity and increasing mortality rates following aneurysmal subarachnoid hemorrhage (SAH). The rate of vasospasm and the outcome (Glasgow Outcome Scale; GOS) especially in poor WFNS grade were retrospectively analyzed over a 6-year period. Patients were divided into three different groups. The first group (pre-group) consisted of 43 patients (grade IV: 31, grade V: 12), who were admitted between 1996 and 1998. When vasospasm occurred, they were mainly treated by papaverine (PPV) and percutaneous transluminal angioplasty (PTA). In the second group (mil-cis group), for the prevention of vasospasm, cisternal irrigation therapy with milrinone was applied in 24 patients (grade IV: 13, grade V: 11), who were admitted in the period between 1999 and 2001. The third group, (w/o mil-cis group), consisted of 30 patients (grade IV: 15, grade V: 15), in whom cisternal irrigation therapy was not able to be carried out. In grade IV, vasospasm was observed in 66% of the patients the first group, 50% in the w/o mil-cis group and significantly less in the mil-cis group (15%, p<0.024). In grade V, the rate of vasospasm was also lower in the mil-cis group but no statistical significance was revealed. Although the rate of favorable outcome in GOS was highest and the rate of death was least in the mil-cis group in both grade IV and V, only the trend was observed. Many factors should be considered, Cisternal irrigation therapy with milrinone reduced the occurrence of vasospasm. However, outcome was not improved because of the initial poor clinical condition.
脑动脉痉挛仍然是动脉瘤性蛛网膜下腔出血(SAH)后发病率和死亡率上升的主要原因。回顾性分析了6年间血管痉挛发生率和预后(格拉斯哥预后评分;GOS),尤其是在世界神经外科联盟(WFNS)分级较差的患者中。患者被分为三个不同的组。第一组(预治疗组)由43例患者组成(Ⅳ级:31例,Ⅴ级:12例),于1996年至1998年入院。当发生血管痉挛时,他们主要接受罂粟碱(PPV)和经皮腔内血管成形术(PTA)治疗。第二组(米力农-脑池灌洗组),为预防血管痉挛,对24例于1999年至2001年期间入院的患者(Ⅳ级:13例,Ⅴ级:11例)采用米力农脑池灌洗治疗。第三组(无米力农-脑池灌洗组)由30例患者组成(Ⅳ级:15例,Ⅴ级:15例),这些患者无法进行脑池灌洗治疗。在Ⅳ级患者中,第一组66%的患者出现血管痉挛,无米力农-脑池灌洗组为50%,而米力农-脑池灌洗组明显较少(15%,p<0.024)。在Ⅴ级患者中,米力农-脑池灌洗组的血管痉挛发生率也较低,但未显示出统计学意义。尽管在Ⅳ级和Ⅴ级患者中,米力农-脑池灌洗组的GOS良好预后率最高,死亡率最低,但仅观察到这种趋势。应考虑许多因素,米力农脑池灌洗治疗可减少血管痉挛的发生。然而,由于初始临床状况较差,预后并未改善。